Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

COMPASS Pathways plc (CMPS) Guidance & Earnings Results

On 2026-05-13 COMPASS Pathways plc reaffirmed guidance: "Cash runway into 2028; NDA submission on track for Q4…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CMPSCOMPASS Pathways plcFollow CMPS — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
1.5B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
13 May 26ReaffirmedCash runway into 2028; NDA submission on track for Q4 2026 · full year
4 Nov 25ReaffirmedFull year 2025 net cash used in operating activities expected to be in the range of $120 million to $145 million. · full year

COMPASS Pathways plc — questions

What guidance did COMPASS Pathways plc give?
On 2026-05-13: "Cash runway into 2028; NDA submission on track for Q4 2026"
When does COMPASS Pathways plc report earnings?
COMPASS Pathways plc's next earnings report is expected on 2026-11-02.

Every figure on this page comes from COMPASS Pathways plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.